Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors

We previously conducted a phase-II study with selumetinib (AZD6244), a small molecule inhibitor of MEK1/2, in advanced biliary tract cancers (BTC), where the primary endpoint was response rate. Several patients experienced objective response. These findings were confirmed with MEK162 in a similar pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Daniel H., Ozer, Hatice Gulcin, Hancioglu, Baris, Lesinski, Gregory B., Timmers, Cynthia, Bekaii-Saab, Tanios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868687/
https://www.ncbi.nlm.nih.gov/pubmed/26683364
http://dx.doi.org/10.18632/oncotarget.6632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868687/
https://www.ncbi.nlm.nih.gov/pubmed/26683364
http://dx.doi.org/10.18632/oncotarget.6632

Ejemplares similares